PLoS ONE (Jan 2016)

Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes.

  • Won Keun Si,
  • Jung Wha Chung,
  • Junhyeon Cho,
  • Joo Yeong Baeg,
  • Eun Sun Jang,
  • Hyuk Yoon,
  • Jaihwan Kim,
  • Cheol Min Shin,
  • Young Soo Park,
  • Jin-Hyeok Hwang,
  • Sook-Hyang Jeong,
  • Nayoung Kim,
  • Dong Ho Lee,
  • Soo Lim,
  • Jin-Wook Kim

DOI
https://doi.org/10.1371/journal.pone.0158066
Journal volume & issue
Vol. 11, no. 6
p. e0158066

Abstract

Read online

Epidemiological data indicate that type 2 diabetes is associated with increased risk of hepatocellular carcinoma (HCC). However, risk stratification for HCC has not been fully elucidated in diabetic population. The aim of this study was to identify potential predictors of HCC in diabetic patients without chronic viral hepatitis. A cohort of 3,544 diabetic patients without chronic viral hepatitis or alcoholic cirrhosis was established and subjects were randomly allocated into a derivation and a validation set. A scoring system was developed by using potential predictors of increased risk of HCC from the Cox proportional hazards model. The performance of the scoring system was tested for validation by using receiver operating characteristics analysis. During median follow-up of 55 months, 36 cases of HCC developed (190 per 100,000 person-years). The 5- and 10-year cumulative incidences of HCC were 1.0%, and 2.2%, respectively. Multivariate Cox regression analysis showed that age > 65 years, low triglyceride levels and high gamma-glutamyl transferase levels were independently associated with an increased risk of HCC. DM-HCC risk score, a weighted sum of scores from these 3 parameters, predicted 10-year development of HCC with area under the receiver operating characteristics curve of 0.86, and discriminated different risk categories for HCC in the derivation and validation cohort. In conclusion, old age, low triglyceride level and high gamma-glutamyl transferase level may help to identify individuals at high risk of developing HCC in diabetic patients without chronic viral hepatitis or alcoholic cirrhosis.